Where is Biological Therapy Going?

Overview

Journal Arthritis Res

Specialty Rheumatology

Date 2000 Nov 30

PMID 11094444

Citations 1

Authors

H Schulze-Koops

J R Kalden

Affiliations

Soon will be listed here.

Abstract

The substantial progress in our understanding of molecular and cellular biology has allowed us to design biological therapeutics ('biologicals') with defined targets and effector functions. These biologicals have greatly contributed to our current knowledge of pathogenetic mechanisms in autoimmune diseases. However, although some of the biologicals have been extremely successful in treating the symptoms of chronic inflammation, biological therapy has not yet met the expectations of permanently silencing the chronic immune response. In this commentary we discuss current concepts and future directions of biological therapy, and the potential usefulness of biologicals as a treatment of human autoimmune diseases in appropriate critical applications with the use of suitably designed agents.

Citing Articles

PLGA nanoparticle--peptide conjugate effectively targets intercellular cell-adhesion molecule-1.

Zhang N, Chittasupho C, Duangrat C, Siahaan T, Berkland C Bioconjug Chem. 2007; 19(1):145-52.

PMID: 17997512 PMC: 2535939. DOI: 10.1021/bc700227z.

References

Maini R, St Clair E, Breedveld F, Furst D, Kalden J, Weisman M . Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 2000; 354(9194):1932-9. DOI: 10.1016/s0140-6736(99)05246-0. View

Brocke S, Gijbels K, Allegretta M, Ferber I, Piercy C, Blankenstein T . Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein. Nature. 1996; 379(6563):343-6. DOI: 10.1038/379343a0. View

Shizuru J, Banks B, Gregory A, Fathman C . Immunotherapy of the nonobese diabetic mouse: treatment with an antibody to T-helper lymphocytes. Science. 1988; 240(4852):659-62. DOI: 10.1126/science.2966437. View

Schulze-Koops H, Davis L, Haverty T, Wacholtz M, Lipsky P . Reduction of Th1 cell activity in the peripheral circulation of patients with rheumatoid arthritis after treatment with a non-depleting humanized monoclonal antibody to CD4. J Rheumatol. 1998; 25(11):2065-76. View

Fowell D, Mason D . Evidence that the T cell repertoire of normal rats contains cells with the potential to cause diabetes. Characterization of the CD4+ T cell subset that inhibits this autoimmune potential. J Exp Med. 1993; 177(3):627-36. PMC: 2190953. DOI: 10.1084/jem.177.3.627. View

Maini R, Taylor P . Anti-cytokine therapy for rheumatoid arthritis. Annu Rev Med. 2000; 51:207-29. DOI: 10.1146/annurev.med.51.1.207. View

Kavanaugh A, Lightfoot E, Lipsky P . Role of CD11/CD18 in adhesion and transendothelial migration of T cells. Analysis utilizing CD18-deficient T cell clones. J Immunol. 1991; 146(12):4149-56. View

Schulze-Koops H, Lipsky P, Kavanaugh A, Davis L . Elevated Th1- or Th0-like cytokine mRNA in peripheral circulation of patients with rheumatoid arthritis. Modulation by treatment with anti-ICAM-1 correlates with clinical benefit. J Immunol. 1995; 155(10):5029-37. View

Davis L, Bogue D, Ramberg J, Lipsky P . Differential utilization of ICAM-1 and VCAM-1 during the adhesion and transendothelial migration of human T lymphocytes. J Immunol. 1991; 147(9):2913-21. View

10.

Cobbold S, Qin S, Waldmann H . Reprogramming the immune system for tolerance with monoclonal antibodies. Semin Immunol. 1990; 2(6):377-87. View

11.

Lipsky P, Davis L, Cush J . The role of cytokines in the pathogenesis of rheumatoid arthritis. Springer Semin Immunopathol. 1989; 11(2):123-62. DOI: 10.1007/BF00197186. View

12.

Rankin E, Choy E, Kassimos D, Kingsley G, Sopwith A, Isenberg D . The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol. 1995; 34(4):334-42. DOI: 10.1093/rheumatology/34.4.334. View

13.

Waldor M, Sriram S, Hardy R, Herzenberg L, Lanier L, Lim M . Reversal of experimental allergic encephalomyelitis with monoclonal antibody to a T-cell subset marker. Science. 1985; 227(4685):415-7. DOI: 10.1126/science.3155574. View

14.

Wofsy D, Seaman W . Successful treatment of autoimmunity in NZB/NZW F1 mice with monoclonal antibody to L3T4. J Exp Med. 1985; 161(2):378-91. PMC: 2187572. DOI: 10.1084/jem.161.2.378. View

15.

Kavanaugh A, St Clair E, McCune W, Braakman T, Lipsky P . Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J Rheumatol. 2000; 27(4):841-50. View

16.

Kavanaugh A, Schulze-Koops H, Davis L, Lipsky P . Repeat treatment of rheumatoid arthritis patients with a murine anti-intercellular adhesion molecule 1 monoclonal antibody. Arthritis Rheum. 1997; 40(5):849-53. DOI: 10.1002/art.1780400511. View

17.

Saoudi A, Kuhn J, Huygen K, De Kozak Y, Velu T, Goldman M . TH2 activated cells prevent experimental autoimmune uveoretinitis, a TH1-dependent autoimmune disease. Eur J Immunol. 1993; 23(12):3096-103. DOI: 10.1002/eji.1830231208. View

18.

Adorini L, Guery J, Trembleau S . Manipulation of the Th1/Th2 cell balance: an approach to treat human autoimmune diseases?. Autoimmunity. 1996; 23(1):53-68. DOI: 10.3109/08916939608995329. View

19.

Skapenko A, Wendler J, Lipsky P, Kalden J, Schulze-Koops H . Altered memory T cell differentiation in patients with early rheumatoid arthritis. J Immunol. 1999; 163(1):491-9. View

20.

Elliott M, Maini R, Feldmann M, Kalden J, Antoni C, Smolen J . Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet. 1994; 344(8930):1105-10. DOI: 10.1016/s0140-6736(94)90628-9. View